The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 24, 2022

Filed:

May. 24, 2020
Applicants:

Yi-hsun Huang, Tainan, TW;

Hua-lin Wu, Taipei, TW;

Inventors:

Yi-Hsun Huang, Tainan, TW;

Hua-Lin Wu, Taipei, TW;

Assignee:

Other;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/36 (2006.01); A61K 38/18 (2006.01); A61P 27/02 (2006.01); A61K 38/17 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01);
U.S. Cl.
CPC ...
A61K 38/366 (2013.01); A61K 38/1783 (2013.01); A61K 38/1866 (2013.01); A61P 27/02 (2018.01); A61K 9/0014 (2013.01); A61K 9/0019 (2013.01); A61K 9/0048 (2013.01); A61K 9/06 (2013.01);
Abstract

The present application relates to dual anti-angiogenic and anti-inflammatory effects of recombinant thrombomodulin domain 1 (TMD1). Specifically, an isolated recombinant polypeptide comprising an amino acid sequence that is at least 80% identical to TMD1 for use in treating an eye disease and/or an eye disorder associated with pathological ocular angiogenesis (POA) in a subject in need thereof is disclosed. The length of the recombinant polypeptide is no more than 200 amino acid residues. The eye disease and/or the eye disorder may be at least one selected from the group consisting of retinopathy of prematurity, diabetic retinopathy, and age-related macular degeneration. Use of TMD1 in the manufacture of a medicament for treating an eye disease and/or an eye disorder associated with vascular endothelial growth factor (VEGF)-induced ocular angiogenesis and/or hypoxia-inducible factor-1α (HIF-1α)-VEGF pathway is also disclosed.


Find Patent Forward Citations

Loading…